Page 2 - Oxford Sciences News Today

Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature New method is being used by Nucleome to unlock the dark matter of the human genome for drug target discovery with exceptional precision Oxford, UK, 10 June 2021 – Nucleome Therapeutics (“Nucleome”), a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease, today announces the publicati...

Date Time Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19 Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus. This breakthrough will improve understanding of how differences in DNA sequences can lead to increased risks of developing many different diseases. The method, which...

How one of the UK’s brightest startups lost its rights to the Oxford vaccine Vaccitech is about to float for $700m in New York, but its vaccine heroics are a mere footnote in its prospectus for potential investors 18 April 2021 • 12:00pm At Oxford University, a long history of scientific triumph has often not been matched by commercial success. Its failure to exploit the discovery of antibiotics haunts the dreaming spires, according to Robin Wright, the chairman of the Covid vaccine develop...

11:50pm EDT| A Virtual Events Startup With $670 Million And The 19 Other Highest-Funded Forbes Under 30 Europe Honorees Illustration by Alexander Wells for Forbes Share to Facebook These companies have all raised over $10 million in funding. While 2020 brought public life to a halt, venture capitalists cut checks at an unmatched volume. The 20 companies on 2021 30 Under 30 Europe Big Money list captured some the largest investments as all raised upwards of $10 million. These companies range fro...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through ... Vaccitech LimitedMarch 17, 2021 GMT OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious disea...

Future Planet Capital: Future Planet Invests in Vaccitechs Series B Financing Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into ...

Posted on 7556 Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into S...

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.

A range of US healthcare funds are backing the Oxford company's efforts to deliver drugs to specific parts of the human body

(1) SpyBiotech has raised $32.5M from leading investors to advance development of its novel "plug and display" vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors Oxford Sciences Innovation and GV also participated Lutz B. Giebel joins as Chairman, strengthening governance as company expands clinical development and builds operational resource OXFORD, United Kingdom, Feb. 10, 2021 (GLOBE NEWSWIRE) -- S...